Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus

To develop hepatitis C virus (HCV) direct-acting antiviral (DAA) drugs that can treat most HCV genotypes and offer higher barriers for treatment-resistant mutations, it is important to study resistance-associated variants (RAVs). Current commercially available RAV detection assays rely on genotype- or subtype-specific template-dependent PCR amplification. These assays are limited to genotypes and subtypes that are often prevalent in developed countries because of availability of public sequence databases.

http://jmd.amjpathol.org/article/S1525-1578(16)30063-0/fulltext?rss=yes

Source: Journal of Molecular Diagnostics - July 5, 2016 Category: Pathology Authors: Bo Wei, John Kang, Miho Kibukawa, Lei Chen, Ping Qiu, Fred Lahser, Matthew Marton, Diane Levitan Tags: Technical Advance Source Type: research